PSMB4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL605949	0.54	15/20
SCHEMBL607010	0.56	12/20
SCHEMBL609327	0.55	12/20
SCHEMBL607553	0.54	12/20
SCHEMBL606932	0.53	12/20
SCHEMBL608381	0.53	12/20
SCHEMBL609081	0.52	12/20
SCHEMBL606926	0.52	12/20
SCHEMBL606344	0.51	12/20
SCHEMBL606616	0.51	12/20
SCHEMBL1327404	0.50	12/20
SCHEMBL607035	0.61	11/20
SCHEMBL609733	0.60	11/20
SCHEMBL609324	0.60	11/20
SCHEMBL605158	0.59	11/20
SCHEMBL606315	0.59	11/20
SCHEMBL1477637	0.57	11/20
SCHEMBL609290	0.57	11/20
SCHEMBL607972	0.55	11/20
SCHEMBL608782	0.54	11/20

Clinical trials — most relevant to PSMB4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	PHASE2	COMPLETED
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	PHASE2	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis	PHASE2	RECRUITING
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma	PHASE2	WITHDRAWN
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy	nan	UNKNOWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Progressive Familial Intrahepatic Cholestasis in Indian Children - Establishing an Indian PFIC Registry	nan	UNKNOWN
Quantification of GADD34 Expression in RA	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Implementation of Molecular Diagnostic Pathways	nan	UNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia	nan	RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMB4 binder may also engage these)

Protein	Name	Similarity
Q3T108	—	1.000	Q3T108 →
P34067	—	0.999	P34067 →
P99026	—	0.997	P99026 →
P28024	—	0.991	P28024 →
P40307	—	0.972	P40307 →
Q5E9K0	—	0.971	Q5E9K0 →
PSMB1	Proteasome component C5	0.970	landscape →
PSMB2	Proteasome Macropain subunit	0.970	landscape →
Q9R1P3	—	0.969	Q9R1P3 →
Q7DLR9	—	0.965	Q7DLR9 →
Q9LST6	—	0.965	Q9LST6 →
Q9IB83	—	0.963	Q9IB83 →
Q2TBX6	—	0.963	Q2TBX6 →
P18421	—	0.963	P18421 →
Q29384	—	0.963	Q29384 →
Q6DRF3	—	0.962	Q6DRF3 →
O23714	—	0.962	O23714 →
Q9IB84	—	0.961	Q9IB84 →
O24633	—	0.958	O24633 →
O09061	—	0.956	O09061 →
O81147	—	0.952	O81147 →
PC	Pyruvate carboxylase, mitochondrial	0.951	landscape →
O48551	—	0.951	O48551 →
Q9P6U7	—	0.951	Q9P6U7 →
O81146	—	0.950	O81146 →
Q9UQY2	—	0.949	Q9UQY2 →
P52873	—	0.948	P52873 →
Q9XG77	—	0.948	Q9XG77 →
P40304	—	0.948	P40304 →
P23724	—	0.947	P23724 →